ConSynance Therapeutics, Inc.
ConSynance Therapeutics is a clinical-stage biopharmaceutical company dedicated to transforming scientific discoveries into therapies for rare central nervous system disorders, with a focus on neuropsychiatric conditions such as Prader-Willi Syndrome. They develop innovative treatments targeting neurotransmitter dysregulation, including CSTI-500, a triple monoamine reuptake inhibitor, and CSTI-100/HBS-102, a Melanin-Concentrating-Hormone Receptor 1 antagonist.
Industries
Nr. of Employees
small (1-50)
ConSynance Therapeutics, Inc.
Rensselaer, New York, United States, North America
Products
CSTI-500
An oral, once-daily triple monoamine reuptake inhibitor designed to modulate serotonin, dopamine, and norepinephrine; developed for hyperphagia and neurobehavioral symptoms in Prader-Willi Syndrome and hypothalamic obesity. Phase I data report safety, ~50-hour half-life, PET target engagement, and bioequivalence of a capsule formulation; program positioned to enter Phase II.
HBS-102 (formerly CSTI-100)
A melanin-concentrating-hormone receptor 1 (MCHR1) antagonist developed for rare neurological indications (including potential applications in REM-sleep dysregulation and energy regulation). Development and commercialization rights are partnered globally except for Greater China, where original developer retains rights.
CSTI-200
A potent and selective GlyT-1 inhibitor in preclinical development intended to treat L-DOPA-induced dyskinesia in Parkinson's disease; characterized by competitive binding properties and favorable ADME/DMPK.
CSTI-500
An oral, once-daily triple monoamine reuptake inhibitor designed to modulate serotonin, dopamine, and norepinephrine; developed for hyperphagia and neurobehavioral symptoms in Prader-Willi Syndrome and hypothalamic obesity. Phase I data report safety, ~50-hour half-life, PET target engagement, and bioequivalence of a capsule formulation; program positioned to enter Phase II.
HBS-102 (formerly CSTI-100)
A melanin-concentrating-hormone receptor 1 (MCHR1) antagonist developed for rare neurological indications (including potential applications in REM-sleep dysregulation and energy regulation). Development and commercialization rights are partnered globally except for Greater China, where original developer retains rights.
CSTI-200
A potent and selective GlyT-1 inhibitor in preclinical development intended to treat L-DOPA-induced dyskinesia in Parkinson's disease; characterized by competitive binding properties and favorable ADME/DMPK.
Services
Collaborative drug development and partnership engagements
Co-development, licensing, and strategic partnership activities with other biopharma organizations and patient advocacy groups to advance rare-disease programs.
Collaborative drug development and partnership engagements
Co-development, licensing, and strategic partnership activities with other biopharma organizations and patient advocacy groups to advance rare-disease programs.
Expertise Areas
- Clinical trial management for rare CNS disorders
- Small-molecule CNS drug discovery and lead optimization
- Translational neuroscience and biomarker qualification
- Pharmacokinetics and DMPK
Key Technologies
- Positron emission tomography (PET) for CNS target engagement
- Triple monoamine reuptake inhibition (small molecule)
- Melanin-concentrating hormone receptor 1 (MCHR1) antagonism
- GlyT-1 inhibition